Literature DB >> 9122043

Effects of the calciotrophic peptides calcitonin and parathyroid hormone on prostate cancer growth and chemotaxis.

C K Ritchie1, K G Thomas, L R Andrews, D J Tindall, L A Fitzpatrick.   

Abstract

BACKGROUND: The most common site of metastases in prostate cancer is the skeleton and occurs in 70-80% of patients with prostate carcinoma. Calciotrophic peptides are important in the growth and development of normal bone matrix.
METHODS: Three human prostate carcinoma cells lines, DU-145, PC-3, and LNCaP, were exposed to varying concentrations of parathyroid hormone (PTH) or calcitonin (CT). Cell proliferation and chemotaxis were assessed.
RESULTS: Proliferation increased in LNCaP cells in a dose-dependent manner following treatment with PTH. Proliferation was not altered in PC-3 cells in response to PTH. Proliferation was decreased in DU-145 and PC-3 cells and increased in LNCaP cells after treatment with CT. Cell chemotaxis was increased in the presence of PTH in DU-145 and PC-3 cells compared to vehicle-treated controls.
CONCLUSIONS: The combined proliferation and chemotaxis data suggest that PTH has a dual role in prostate carcinoma resulting in an increase in the number and migration of selected prostate cancer cells. With CT, chemotaxis was unchanged in the DU-145 and PC-3 cells and significantly elevated in the LNCaP cell line. The calciotrophic hormones, PTH and CT, may play an integral role in the regulation of prostate cell growth and metastases.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9122043     DOI: 10.1002/(sici)1097-0045(19970215)30:3<183::aid-pros6>3.0.co;2-n

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  14 in total

Review 1.  [Physical activity for primary prevention of prostate cancer. Possible mechanisms].

Authors:  H C Heitkamp; I Jelas
Journal:  Urologe A       Date:  2012-04       Impact factor: 0.639

2.  Neuroendocrine differentiation in prostate cancer.

Authors:  Yin Sun; Junyang Niu; Jiaoti Huang
Journal:  Am J Transl Res       Date:  2009-02-05       Impact factor: 4.060

3.  Identification of a small molecule class to enhance cell-cell adhesion and attenuate prostate tumor growth and metastasis.

Authors:  Girish V Shah; Anbalagan Muralidharan; Shibu Thomas; Mitan Gokulgandhi; Mudit Mudit; Mohammad Khanfar; Khalid El Sayed
Journal:  Mol Cancer Ther       Date:  2009-03-10       Impact factor: 6.261

4.  Calcitonin receptor-stimulated migration of prostate cancer cells is mediated by urokinase receptor-integrin signaling.

Authors:  Shibu Thomas; Maurizio Chiriva-Internati; Girish V Shah
Journal:  Clin Exp Metastasis       Date:  2007-05-09       Impact factor: 5.150

5.  Serum calcium and incident and fatal prostate cancer in the National Health and Nutrition Examination Survey.

Authors:  Halcyon G Skinner; Gary G Schwartz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-09       Impact factor: 4.254

6.  The relation of serum parathyroid hormone and serum calcium to serum levels of prostate-specific antigen: a population-based study.

Authors:  Halcyon G Skinner; Gary G Schwartz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-10-27       Impact factor: 4.254

7.  A prospective study of total and ionized serum calcium and fatal prostate cancer.

Authors:  Halcyon G Skinner; Gary G Schwartz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-02-03       Impact factor: 4.254

Review 8.  Does salmon calcitonin cause cancer? A review and meta-analysis.

Authors:  G Wells; J Chernoff; J P Gilligan; D S Krause
Journal:  Osteoporos Int       Date:  2015-10-05       Impact factor: 4.507

9.  The calcimimetic R-568 induces apoptotic cell death in prostate cancer cells.

Authors:  Huaifu Li; Guofeng Ruan; Zhijun Li; Ziwei Liu; Xiaoqing Zheng; Hao Zheng; Guangming Cheng; Benyi Li; Ming Zhan
Journal:  J Exp Clin Cancer Res       Date:  2009-07-14

10.  Evaluation of Serum Calcium as a Predictor of Biochemical Recurrence following Salvage Radiation Therapy for Prostate Cancer.

Authors:  Jennifer L Peterson; Steven J Buskirk; Michael G Heckman; Alexander S Parker; Nancy N Diehl; Katherine S Tzou; Nitesh N Paryani; Stephen J Ko; Larry C Daugherty; Laura A Vallow; Thomas M Pisansky
Journal:  ISRN Oncol       Date:  2013-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.